We are analyzing https://link.springer.com/article/10.1007/s10549-016-3807-y.

Title:
Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer | Breast Cancer Research and Treatment
Description:
Anti-estrogen and anti-HER2 treatments have been among the first and most successful examples of targeted therapy for breast cancer (BC). However, the treatment of triple-negative BC (TNBC) that lack estrogen receptor expression or HER2 amplification remains a major challenge. We previously discovered that approximately two-thirds of TNBCs express vitamin D receptor (VDR) and/or androgen receptor (AR) and hypothesized that TNBCs co-expressing AR and VDR (HR2-av TNBC) could be treated by targeting both of these hormone receptors. To evaluate the feasibility of VDR/AR-targeted therapy in TNBC, we characterized 15 different BC lines and identified 2 HR2-av TNBC lines and examined the changes in their phenotype, viability, and proliferation after VDR and AR-targeted treatment. Treatment of BC cell lines with VDR or AR agonists inhibited cell viability in a receptor-dependent manner, and their combination appeared to inhibit cell viability additively. Moreover, cell viability was further decreased when AR/VDR agonist hormones were combined with chemotherapeutic drugs. The mechanisms of inhibition by AR/VDR agonist hormones included cell cycle arrest and apoptosis in TNBC cell lines. In addition, AR/VDR agonist hormones induced differentiation and inhibited cancer stem cells (CSCs) measured by reduction in tumorsphere formation efficiency, high aldehyde dehydrogenase activity, and CSC markers. Surprisingly, we found that AR antagonists inhibited proliferation of most BC cell lines in an AR-independent manner, raising questions regarding their mechanism of action. In summary, AR/VDR-targeted agonist hormone therapy can inhibit HR2-av TNBC through multiple mechanisms in a receptor-dependent manner and can be combined with chemotherapy.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Telecommunications

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,625,932 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

cell, cancer, lines, pubmed, breast, google, scholar, article, cells, cas, vdr, fig, tnbc, receptor, treatment, calcitriol, combination, dht, androgen, agonists, cal, proliferation, mfm, therapy, bar, hrav, vitamin, expression, bars, effect, viability, antagonists, stem, central, res, treated, found, human, days, drug, effects, drugs, response, black, agonist, suppl, analysis, apoptosis, additive, hatched,

Topics {✒️}

n-butyl-n-methyl-11-[16′ alpha-chloro-3′ pcr-based array er+/luma versus tnbc/basal human nuclear receptors sur le mecanisme triple-negative breast cancer article download pdf effective anti-er therapies vdr hr-targeted therapies full size image hr2-av cell lines cyto-id® fluorescent dye iodo-nitrotetrazolium chloride overnight triene-7′ alpha-yl] undecanamide er−/her2+/ar+ cell lines inhibit hr2-av tnbc long-term tissue culture vdr-targeted hormone therapy hr2-av tnbc mfm-223 cancer stem cells—perspectives phenol red-free media estrogen-induced cell proliferation hr-targeted therapies androgen receptor-targeted therapy induce anti-tumor activity triple-negative bc human breast cancer sum-159pt cell lines y-axis represents triple-negative bcs ar/vdr agonist hormones vdr/ar-targeted therapy breast cancer based related subjects previously published profiles hr2-av tnbc early breast cancer hr2-av designation cancer stem cell full access lickley la privacy choices/manage cookies du-145 cell line cancer cell lines bliss independence criterion cellular pharmacology breast cancers adrenalectomized human females tissue-specific drug response breast cancer risk

Questions {❓}

Alison MR, Lim SM, Nicholson LJ (2011) Cancer stem cells: problems for therapy?
Anestis A, Karamouzis MV, Dalagiorgou G, Papavassiliou AG (2015) Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer
         description:Anti-estrogen and anti-HER2 treatments have been among the first and most successful examples of targeted therapy for breast cancer (BC). However, the treatment of triple-negative BC (TNBC) that lack estrogen receptor expression or HER2 amplification remains a major challenge. We previously discovered that approximately two-thirds of TNBCs express vitamin D receptor (VDR) and/or androgen receptor (AR) and hypothesized that TNBCs co-expressing AR and VDR (HR2-av TNBC) could be treated by targeting both of these hormone receptors. To evaluate the feasibility of VDR/AR-targeted therapy in TNBC, we characterized 15 different BC lines and identified 2 HR2-av TNBC lines and examined the changes in their phenotype, viability, and proliferation after VDR and AR-targeted treatment. Treatment of BC cell lines with VDR or AR agonists inhibited cell viability in a receptor-dependent manner, and their combination appeared to inhibit cell viability additively. Moreover, cell viability was further decreased when AR/VDR agonist hormones were combined with chemotherapeutic drugs. The mechanisms of inhibition by AR/VDR agonist hormones included cell cycle arrest and apoptosis in TNBC cell lines. In addition, AR/VDR agonist hormones induced differentiation and inhibited cancer stem cells (CSCs) measured by reduction in tumorsphere formation efficiency, high aldehyde dehydrogenase activity, and CSC markers. Surprisingly, we found that AR antagonists inhibited proliferation of most BC cell lines in an AR-independent manner, raising questions regarding their mechanism of action. In summary, AR/VDR-targeted agonist hormone therapy can inhibit HR2-av TNBC through multiple mechanisms in a receptor-dependent manner and can be combined with chemotherapy.
         datePublished:2016-04-27T00:00:00Z
         dateModified:2016-04-27T00:00:00Z
         pageStart:77
         pageEnd:90
         sameAs:https://doi.org/10.1007/s10549-016-3807-y
         keywords:
            Hormone receptor
            Triple-negative breast cancer
            Androgen receptor
            Vitamin D receptor
            Cancer stem cells
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-016-3807-y/MediaObjects/10549_2016_3807_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-016-3807-y/MediaObjects/10549_2016_3807_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-016-3807-y/MediaObjects/10549_2016_3807_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-016-3807-y/MediaObjects/10549_2016_3807_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-016-3807-y/MediaObjects/10549_2016_3807_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-016-3807-y/MediaObjects/10549_2016_3807_Fig6_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-016-3807-y/MediaObjects/10549_2016_3807_Fig7_HTML.gif
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:157
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:A. Thakkar
               affiliation:
                     name:University of Miami
                     address:
                        name:Sylvester Comprehensive Cancer Center, Department of Pathology, Braman Family Breast Cancer Institute and Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, USA
                        type:PostalAddress
                     type:Organization
                     name:University of Miami
                     address:
                        name:Sheila and David Fuente Graduate Program in Cancer Biology, University of Miami, Miami, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:B. Wang
               affiliation:
                     name:University of Miami
                     address:
                        name:Sylvester Comprehensive Cancer Center, Department of Pathology, Braman Family Breast Cancer Institute and Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. Picon-Ruiz
               affiliation:
                     name:University of Miami
                     address:
                        name:Sylvester Comprehensive Cancer Center, Department of Pathology, Braman Family Breast Cancer Institute and Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:P. Buchwald
               affiliation:
                     name:University of Miami
                     address:
                        name:Department of Molecular and Cellular Pharmacology, University of Miami, Miami, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Tan A. Ince
               affiliation:
                     name:University of Miami
                     address:
                        name:Sylvester Comprehensive Cancer Center, Department of Pathology, Braman Family Breast Cancer Institute and Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, USA
                        type:PostalAddress
                     type:Organization
                     name:
                     address:
                        name:Miami, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer
      description:Anti-estrogen and anti-HER2 treatments have been among the first and most successful examples of targeted therapy for breast cancer (BC). However, the treatment of triple-negative BC (TNBC) that lack estrogen receptor expression or HER2 amplification remains a major challenge. We previously discovered that approximately two-thirds of TNBCs express vitamin D receptor (VDR) and/or androgen receptor (AR) and hypothesized that TNBCs co-expressing AR and VDR (HR2-av TNBC) could be treated by targeting both of these hormone receptors. To evaluate the feasibility of VDR/AR-targeted therapy in TNBC, we characterized 15 different BC lines and identified 2 HR2-av TNBC lines and examined the changes in their phenotype, viability, and proliferation after VDR and AR-targeted treatment. Treatment of BC cell lines with VDR or AR agonists inhibited cell viability in a receptor-dependent manner, and their combination appeared to inhibit cell viability additively. Moreover, cell viability was further decreased when AR/VDR agonist hormones were combined with chemotherapeutic drugs. The mechanisms of inhibition by AR/VDR agonist hormones included cell cycle arrest and apoptosis in TNBC cell lines. In addition, AR/VDR agonist hormones induced differentiation and inhibited cancer stem cells (CSCs) measured by reduction in tumorsphere formation efficiency, high aldehyde dehydrogenase activity, and CSC markers. Surprisingly, we found that AR antagonists inhibited proliferation of most BC cell lines in an AR-independent manner, raising questions regarding their mechanism of action. In summary, AR/VDR-targeted agonist hormone therapy can inhibit HR2-av TNBC through multiple mechanisms in a receptor-dependent manner and can be combined with chemotherapy.
      datePublished:2016-04-27T00:00:00Z
      dateModified:2016-04-27T00:00:00Z
      pageStart:77
      pageEnd:90
      sameAs:https://doi.org/10.1007/s10549-016-3807-y
      keywords:
         Hormone receptor
         Triple-negative breast cancer
         Androgen receptor
         Vitamin D receptor
         Cancer stem cells
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-016-3807-y/MediaObjects/10549_2016_3807_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-016-3807-y/MediaObjects/10549_2016_3807_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-016-3807-y/MediaObjects/10549_2016_3807_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-016-3807-y/MediaObjects/10549_2016_3807_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-016-3807-y/MediaObjects/10549_2016_3807_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-016-3807-y/MediaObjects/10549_2016_3807_Fig6_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-016-3807-y/MediaObjects/10549_2016_3807_Fig7_HTML.gif
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:157
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:A. Thakkar
            affiliation:
                  name:University of Miami
                  address:
                     name:Sylvester Comprehensive Cancer Center, Department of Pathology, Braman Family Breast Cancer Institute and Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, USA
                     type:PostalAddress
                  type:Organization
                  name:University of Miami
                  address:
                     name:Sheila and David Fuente Graduate Program in Cancer Biology, University of Miami, Miami, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:B. Wang
            affiliation:
                  name:University of Miami
                  address:
                     name:Sylvester Comprehensive Cancer Center, Department of Pathology, Braman Family Breast Cancer Institute and Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. Picon-Ruiz
            affiliation:
                  name:University of Miami
                  address:
                     name:Sylvester Comprehensive Cancer Center, Department of Pathology, Braman Family Breast Cancer Institute and Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:P. Buchwald
            affiliation:
                  name:University of Miami
                  address:
                     name:Department of Molecular and Cellular Pharmacology, University of Miami, Miami, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Tan A. Ince
            affiliation:
                  name:University of Miami
                  address:
                     name:Sylvester Comprehensive Cancer Center, Department of Pathology, Braman Family Breast Cancer Institute and Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, USA
                     type:PostalAddress
                  type:Organization
                  name:
                  address:
                     name:Miami, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:157
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Miami
      address:
         name:Sylvester Comprehensive Cancer Center, Department of Pathology, Braman Family Breast Cancer Institute and Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, USA
         type:PostalAddress
      name:University of Miami
      address:
         name:Sheila and David Fuente Graduate Program in Cancer Biology, University of Miami, Miami, USA
         type:PostalAddress
      name:University of Miami
      address:
         name:Sylvester Comprehensive Cancer Center, Department of Pathology, Braman Family Breast Cancer Institute and Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, USA
         type:PostalAddress
      name:University of Miami
      address:
         name:Sylvester Comprehensive Cancer Center, Department of Pathology, Braman Family Breast Cancer Institute and Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, USA
         type:PostalAddress
      name:University of Miami
      address:
         name:Department of Molecular and Cellular Pharmacology, University of Miami, Miami, USA
         type:PostalAddress
      name:University of Miami
      address:
         name:Sylvester Comprehensive Cancer Center, Department of Pathology, Braman Family Breast Cancer Institute and Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, USA
         type:PostalAddress
      name:
      address:
         name:Miami, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:A. Thakkar
      affiliation:
            name:University of Miami
            address:
               name:Sylvester Comprehensive Cancer Center, Department of Pathology, Braman Family Breast Cancer Institute and Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, USA
               type:PostalAddress
            type:Organization
            name:University of Miami
            address:
               name:Sheila and David Fuente Graduate Program in Cancer Biology, University of Miami, Miami, USA
               type:PostalAddress
            type:Organization
      name:B. Wang
      affiliation:
            name:University of Miami
            address:
               name:Sylvester Comprehensive Cancer Center, Department of Pathology, Braman Family Breast Cancer Institute and Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, USA
               type:PostalAddress
            type:Organization
      name:M. Picon-Ruiz
      affiliation:
            name:University of Miami
            address:
               name:Sylvester Comprehensive Cancer Center, Department of Pathology, Braman Family Breast Cancer Institute and Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, USA
               type:PostalAddress
            type:Organization
      name:P. Buchwald
      affiliation:
            name:University of Miami
            address:
               name:Department of Molecular and Cellular Pharmacology, University of Miami, Miami, USA
               type:PostalAddress
            type:Organization
      name:Tan A. Ince
      affiliation:
            name:University of Miami
            address:
               name:Sylvester Comprehensive Cancer Center, Department of Pathology, Braman Family Breast Cancer Institute and Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, USA
               type:PostalAddress
            type:Organization
            name:
            address:
               name:Miami, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Sylvester Comprehensive Cancer Center, Department of Pathology, Braman Family Breast Cancer Institute and Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, USA
      name:Sheila and David Fuente Graduate Program in Cancer Biology, University of Miami, Miami, USA
      name:Sylvester Comprehensive Cancer Center, Department of Pathology, Braman Family Breast Cancer Institute and Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, USA
      name:Sylvester Comprehensive Cancer Center, Department of Pathology, Braman Family Breast Cancer Institute and Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, USA
      name:Department of Molecular and Cellular Pharmacology, University of Miami, Miami, USA
      name:Sylvester Comprehensive Cancer Center, Department of Pathology, Braman Family Breast Cancer Institute and Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, USA
      name:Miami, USA

External Links {🔗}(327)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Moment.js
Prism.js

CDN Services {📦}

Crossref

6.05s.

LINK . SPRINGER . COM {}